array:23 [
  "pii" => "S1699258X0900240X"
  "issn" => "1699258X"
  "doi" => "10.1016/j.reuma.2009.10.002"
  "estado" => "S300"
  "fechaPublicacion" => "2010-01-01"
  "aid" => "128"
  "copyright" => "Elsevier España, S.L. All rights reserved"
  "copyrightAnyo" => "2009"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "sco"
  "cita" => "Reumatol Clin. 2010;6:3-4"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 5570
    "formatos" => array:3 [
      "EPUB" => 138
      "HTML" => 4471
      "PDF" => 961
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S1699258X09001247"
    "issn" => "1699258X"
    "doi" => "10.1016/j.reuma.2009.01.008"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "75"
    "copyright" => "Elsevier España, S.L"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Reumatol Clin. 2010;6:5-10"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 65630
      "formatos" => array:3 [
        "EPUB" => 170
        "HTML" => 54628
        "PDF" => 10832
      ]
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
      "titulo" => "Hiperlaxitud ligamentosa &#40;test de Beighton&#41; en la poblaci&#243;n escolar de 8 a 12 a&#241;os de la provincia de Granada"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "5"
          "paginaFinal" => "10"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Hiperlaxity ligamentous &#40;Beighton test&#41; in the 8 to 12 years of age school population in the province of Granada"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1372
              "Ancho" => 1625
              "Tamanyo" => 219140
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p class="elsevierStyleSimplePara elsevierViewall">Sectorizaci&#243;n de las zonas de estudio de la provincia de Granada&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#233;lix Zurita Ortega, Luis Ruiz Rodr&#237;guez, Asunci&#243;n Mart&#237;nez Mart&#237;nez, Manuel Fern&#225;ndez S&#225;nchez, Concepci&#243;n Rodr&#237;guez Paiz, Remedios L&#243;pez Liria"
          "autores" => array:6 [
            0 => array:3 [
              "Iniciales" => "F."
              "nombre" => "F&#233;lix"
              "apellidos" => "Zurita Ortega"
            ]
            1 => array:3 [
              "Iniciales" => "L."
              "nombre" => "Luis"
              "apellidos" => "Ruiz Rodr&#237;guez"
            ]
            2 => array:3 [
              "Iniciales" => "A."
              "nombre" => "Asunci&#243;n"
              "apellidos" => "Mart&#237;nez Mart&#237;nez"
            ]
            3 => array:3 [
              "Iniciales" => "M."
              "nombre" => "Manuel"
              "apellidos" => "Fern&#225;ndez S&#225;nchez"
            ]
            4 => array:3 [
              "Iniciales" => "C."
              "nombre" => "Concepci&#243;n"
              "apellidos" => "Rodr&#237;guez Paiz"
            ]
            5 => array:3 [
              "Iniciales" => "R."
              "nombre" => "Remedios"
              "apellidos" => "L&#243;pez Liria"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X09001247?idApp=UINPBA00004M"
    "url" => "/1699258X/0000000600000001/v1_201305061824/S1699258X09001247/v1_201305061824/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S1699258X0900031X"
    "issn" => "1699258X"
    "doi" => "10.1016/j.reuma.2009.01.002"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "30"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "sco"
    "cita" => "Reumatol Clin. 2010;6:1-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 15587
      "formatos" => array:3 [
        "EPUB" => 141
        "HTML" => 14131
        "PDF" => 1315
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Gen&#233;tica del lupus eritematoso generalizado&#46; &#191;Qu&#233; se sabe y a d&#243;nde se va&#63;"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "1"
          "paginaFinal" => "2"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Systemic lupus erythematosus&#46; &#171;What do we know and where are we heading&#63;&#187;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Marta Eugenia Alarc&#243;n Riquelme"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Marta Eugenia"
              "apellidos" => "Alarc&#243;n Riquelme"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X0900031X?idApp=UINPBA00004M"
    "url" => "/1699258X/0000000600000001/v1_201305061824/S1699258X0900031X/v1_201305061824/es/main.assets"
  ]
  "en" => array:11 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
    "titulo" => "New drugs for rheumatoid arthritis&#58; The industry point of view"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "3"
        "paginaFinal" => "4"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Stephen H&#46; Polmar"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Stephen H&#46;"
            "apellidos" => "Polmar"
            "email" => array:1 [
              0 => "stephen&#64;polmarconsulting&#46;com"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:1 [
            "entidad" => "Polmar Pharma Consulting&#44; Woodbridge&#44; Connecticut&#44; USA"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Nuevos medicamentos contra la artritis reumatoide&#46; El punto de vista de la industria"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p class="elsevierStylePara elsevierViewall">During the past decade there has been impressive progress in the treatment of rheumatoid arthritis &#40;RA&#41;&#46; Beginning with the regulatory approvals of etanercept and leflunomide in 1998&#44; a total of 10 new disease-modifying anti-rheumatic drugs &#40;DMARDs&#41; have been approved for the treatment of RA&#46; Of these 10 drugs&#44; 9 are biologicals &#40;i&#46;e&#46; monoclonal antibodies&#44; soluble receptors or fusion proteins&#41; and only one&#44; leflunomide&#44; is a small molecule&#44; non-biological DMARD&#46; The biologicals include 5 TNF-blocking agents &#40;etanercept&#44; infliximab&#44; adalimumab&#44; golimumab and certolizumab pegol&#41;&#44; an IL-1 beta blocking recombinant soluble receptor &#40;anakinra&#41;&#44; a T-cell co-stimulatory receptor blocking fusion protein &#40;CTLA4-Ig&#44; abatacept&#41;&#44; a B-cell depleting monoclonal antibody &#40; anti-CD20&#44; rituximab&#41; and most recently&#44; a monoclonal antibody directed against the IL-6 receptor &#40;tocilizumab&#41;&#46; This is an impressive record for this sector of the pharmaceutical industry during a period when the overall productivity of the industry&#44;as measured by the introduction of new drugs to the market&#44; declined&#46;</p><p class="elsevierStylePara elsevierViewall">While currently therapy for new patients with RA is initiated with one or more non-biological DMARDs &#40;most frequently methotrexate&#41;&#44; supplemented with non-steroidal anti-inflammatory drugs &#40;NSAIDS&#41; and corticosteroids&#44; the advent of the biological agents has fostered earlier and more aggressive therapy<a class="elsevierStyleCrossRef" href="#bib1"><span class="elsevierStyleSup">1</span></a>&#46; For many patients with an inadequate response to non-biological DMARDs&#44; addition of a TNF blocking agent results in a significant improvement in signs and symptoms of disease as measured by American College of Rheumatology &#40;ACR&#41; scores&#46; Furthermore&#44; as demonstrated in the Premier study&#44; the combination of methotrexate with an anti-TNF alpha monoclonal antibody showed superior efficacy compared to either drug used as monotherapy for patients with early aggressive disease who are na&#239;ve to methotrexate<a class="elsevierStyleCrossRef" href="#bib2"><span class="elsevierStyleSup">2</span></a>&#46; The most stringent regulatory criterion of efficacy in clinical development is &#8220;Major Clinical Response&#8221;&#44; defined as the patient achieving an ACR 70 response for a continuous period of six months&#46; In the Premier study after 2 years&#44; 49&#37; of patients in the combination therapy group achieved a Major Clinical Response compared to 28&#37; and 25&#37; for methotrexate alone and adalimumab alone&#44; respectively&#46; In the development of new drugs for RA&#44; pharmaceutical companies chose a so-called &#8220;Gold Standard&#8221; therapy to which all new therapeutic agents will be compared with respect to efficacy and safety&#46; For this purpose&#44; most pharmaceutical companies now consider the combination of methotrexate with a TNF-blocking agent as the Gold Standard for RA treatment&#46;</p><p class="elsevierStylePara elsevierViewall">When considering investment in a drug discovery and drug development program&#44; a pharmaceutical company must consider the unmet medical need in a particular disease&#44; the size of the patient population anticipated at the time the new drug will enter the market and the competition from other companies&#46; Most importantly the pharmaceutical company must attempt to determine if the mechanism of action of the new drug will translate into increased efficacy and an acceptable safety profile to permit both the approval of the drug by regulatory authorities and allow it to compete successfully against drugs that will be on the market&#46; Ultimately&#44; the success or failure of a new drug depends upon its ability achieve &#8220;market penetration&#8221;&#44; that is to gain a larger share of the market than its competitors&#46;</p><p class="elsevierStylePara elsevierViewall">At the present time rheumatologists and their patients are reasonably satisfied with the Gold Standard therapy with respect to both its degree of efficacy and safety&#44; but clearly there is room for improvement&#46; Gold Standard therapy achieves a Major Clinical Response in only half of the patients and approximately 30&#37; do not even achieve an ACR 20 response&#46; However&#44; the consensus among pharmaceutical companies is that the new biologicals currently in clinical development are unlikely to displace the TNF blocking agents which they consider &#8220;first-line biological therapy&#8221;&#46; This is due both to their efficacy and the generally favorable 15-year safety record of these agents&#46; In contrast&#44; the biologicals currently used in &#8220;second-line biological therapy&#8221; such as anakinra&#44; abatacept&#44; rituximab and tocilizumab may be vulnerable to replacement due either to sub-optimal efficacy or unanswered questions about their long-term safety&#46; Two anti-CD20 B-cell depleting antibodies&#44; ocrelizumab and ofatumumab&#44; are being positioned as replacements for rituximab&#46; However&#44; a potential complicating factor&#44; not only for the companies developing anti-CD 20 monoclonal antibodies&#44; but also for those companies currently marketing and developing other biologicals&#44; is the possible entry of generic biologicals into the market place in near future&#46; Starting with the expiry of the etanercept patent in 2012 in the US&#44; the patents for all current first and second line biologicals will expired by 2018&#46; The potential impact of generic biologicals on the market is unknown at this time and will depend to a great extent upon the regulatory requirements for generic biologicals and the ability of pharmaceutical companies to delay their entry into the market by legal action&#46; Nonetheless&#44; there should still be opportunities for new biologicals which act on new targets or by novel mechanisms to penetrate the RA market provided that they can demonstrate superior efficacy to currently available biologicals and acceptable safety profiles&#46; For example&#44; anti-IL-17 monoclonal antibodies&#44; which has shown remarkable efficacy in psoriasis&#44; are now in clinical trials in RA&#46; Other biologicals in early clinical development include anti-IL-18&#44; anti-IL-18 receptor&#44; anti-CD 16&#44; anti-GMCSF and anti-IP-10&#46;</p><p class="elsevierStylePara elsevierViewall">Many in the pharmaceutical industry believed that the era of biological DMARD therapy for RA would be relatively short and would be a transitional period after which the biologicals would be largely replaced by oral small molecule therapies&#46; This has been shown to be incorrect&#46; The development of new oral therapies has proven to be extremely challenging both with respect to achieving adequate efficacy and acceptable safety&#46; The attrition of new small molecule drugs in RA clinical development has been extremely high&#46; For example&#44; in 2007 seven pharmaceutical companies had p38 MAP kinase inhibitors in phase II and now only one remains&#46; There is a long list of compounds whose development has been recently discontinued including chemokine inhibitors &#40;CCR1 and CCR2&#41;&#44; an iNOS inhibitor&#44; IKK-2 inhibitor and P2X7 receptor antagonists&#46; There are&#44; however&#44; two small molecule drug classes that are currently in late stage clinical development&#44; janus-associated kinase &#40;JAK&#41; inhibitors and spleen tyrosine kinase &#40;SYK&#41; inhibitors&#46; These drugs have shown efficacy similar to TNF-blocking agents in phase II clinical trials&#44; but safety concerns exist such as elevation of liver enzymes and LDL cholesterol&#44; the clinical significance of which remain to be determined&#46; The goal of pharmaceutical companies developing oral small molecule therapeutic agents is to attempt to replace the first-line biologicals in patients who have had an inadequate response to methotrexate&#46; To achieve this goal&#44; these new drugs will have to be at least as efficacious as the TNF-blockers and also have an acceptable safety profile that permits co-administration with methotrexate without an additional risk of hepatotoxicity&#46; Alternatively&#44; such compounds would have to show efficacy as monotherapy comparable to a TNF-blocking agent &#43; methotrexate&#46; These new oral DMARDS would have a potential competitive advantage of convenience for patients and would be expected to cost less than the biologicals&#44; therefore being favored by health authorities and insurance companies&#46; However&#44; the extent to which some of the new oral agents will ultimately penetrate the market will depend on their efficacy in phase III trials and safety profiles&#44; the degree to which patients will favor daily oral therapy versus every other week or monthly injections and also the possible entry of generic biologicals into the market at a substantially lower cost than current brand-name biologicals&#46;</p><p class="elsevierStylePara elsevierViewall">The pharmaceutical industry&#44; together with academic researchers&#44; has explored many potential drug targets for RA therapy&#46; While there have been some successes there have been many more failures&#44; nonetheless&#44; pharmaceutical companies continue to invest in research and development of new drugs for RA&#46; At the present time&#44; approximately 65 drugs are in phase I or phase II&#44; 63&#37; of these are biologicals and 37&#37; are small molecules&#46; The overwhelming majority of these drugs target the immune system&#46; In a disease such as RA in which combination therapy is frequently employed&#44; addition of yet another drug that targets the immune system along with the Gold Standard therapy can result in an unacceptably high incidence of severe infections&#46; In recognition of the limit to which the immune system can be safely manipulated&#44; academic researchers&#44; biotech companies and some pharmaceutical companies are starting to focus on other tissues &#40;e&#46;g&#46; synovial fibroblasts and osteoclasts&#41; or processes &#40;e&#46;g&#46; angiogenesis&#41; which play an important role in the pathogenesis of RA but which are not critical for host defense against infection or malignancy&#46;</p><p class="elsevierStylePara elsevierViewall">In the next 5&#8211;10 years&#44; rheumatologists and their patients should not expect a rate of introduction of new drugs for RA as high as that which occurred during the last decade&#46; However&#44; since a substantial number of patients still do not have their disease fully controlled by current therapy&#44; one can anticipate that the pharmaceutical industry will continue to invest in research and development of both biological- and non-biological drugs to meet the needs of these patients&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:2 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;G&#46; Saag"
                            1 => "G&#46;G&#46; Teng"
                            2 => "N&#46;M&#46; Patkar"
                            3 => "J&#46; Anuntiyo"
                            4 => "C&#46; Finney"
                            5 => "J&#46;R&#46; Curtis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23721"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "59"
                        "paginaInicial" => "762"
                        "paginaFinal" => "784"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18512708"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The PREMIER study&#58; A multicenter&#44; randomized&#44; double-blind&#44; clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early&#44; aggressive rheumatoid arthritis who had not had previous methotrexate treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;C&#46; Breedveld"
                            1 => "M&#46;H&#46; Weisman"
                            2 => "A&#46;F&#46; Kavanaugh"
                            3 => "S&#46;B&#46; Cohen"
                            4 => "K&#46; Pavelka"
                            5 => "R&#46; van Vollenhoven"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21519"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2006"
                        "volumen" => "54"
                        "paginaInicial" => "26"
                        "paginaFinal" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16385520"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/1699258X/0000000600000001/v1_201305061824/S1699258X0900240X/v1_201305061824/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "17498"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Editorial"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/1699258X/0000000600000001/v1_201305061824/S1699258X0900240X/v1_201305061824/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X0900240X?idApp=UINPBA00004M"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Editorial
New drugs for rheumatoid arthritis: The industry point of view
Nuevos medicamentos contra la artritis reumatoide. El punto de vista de la industria
Stephen H. Polmar
Polmar Pharma Consulting, Woodbridge, Connecticut, USA
Leído
16112
Veces
se ha leído el artículo
3390
Total PDF
12722
Total HTML
Compartir estadísticas
 array:23 [
  "pii" => "S1699258X0900240X"
  "issn" => "1699258X"
  "doi" => "10.1016/j.reuma.2009.10.002"
  "estado" => "S300"
  "fechaPublicacion" => "2010-01-01"
  "aid" => "128"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L. All rights reserved"
  "copyrightAnyo" => "2009"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "sco"
  "cita" => "Reumatol Clin. 2010;6:3-4"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 5570
    "formatos" => array:3 [
      "EPUB" => 138
      "HTML" => 4471
      "PDF" => 961
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S1699258X09001247"
    "issn" => "1699258X"
    "doi" => "10.1016/j.reuma.2009.01.008"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "75"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Reumatol Clin. 2010;6:5-10"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 65630
      "formatos" => array:3 [
        "EPUB" => 170
        "HTML" => 54628
        "PDF" => 10832
      ]
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
      "titulo" => "Hiperlaxitud ligamentosa &#40;test de Beighton&#41; en la poblaci&#243;n escolar de 8 a 12 a&#241;os de la provincia de Granada"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "5"
          "paginaFinal" => "10"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Hiperlaxity ligamentous &#40;Beighton test&#41; in the 8 to 12 years of age school population in the province of Granada"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig1"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1372
              "Ancho" => 1625
              "Tamanyo" => 219140
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p class="elsevierStyleSimplePara elsevierViewall">Sectorizaci&#243;n de las zonas de estudio de la provincia de Granada&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "F&#233;lix Zurita Ortega, Luis Ruiz Rodr&#237;guez, Asunci&#243;n Mart&#237;nez Mart&#237;nez, Manuel Fern&#225;ndez S&#225;nchez, Concepci&#243;n Rodr&#237;guez Paiz, Remedios L&#243;pez Liria"
          "autores" => array:6 [
            0 => array:3 [
              "Iniciales" => "F."
              "nombre" => "F&#233;lix"
              "apellidos" => "Zurita Ortega"
            ]
            1 => array:3 [
              "Iniciales" => "L."
              "nombre" => "Luis"
              "apellidos" => "Ruiz Rodr&#237;guez"
            ]
            2 => array:3 [
              "Iniciales" => "A."
              "nombre" => "Asunci&#243;n"
              "apellidos" => "Mart&#237;nez Mart&#237;nez"
            ]
            3 => array:3 [
              "Iniciales" => "M."
              "nombre" => "Manuel"
              "apellidos" => "Fern&#225;ndez S&#225;nchez"
            ]
            4 => array:3 [
              "Iniciales" => "C."
              "nombre" => "Concepci&#243;n"
              "apellidos" => "Rodr&#237;guez Paiz"
            ]
            5 => array:3 [
              "Iniciales" => "R."
              "nombre" => "Remedios"
              "apellidos" => "L&#243;pez Liria"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X09001247?idApp=UINPBA00004M"
    "url" => "/1699258X/0000000600000001/v1_201305061824/S1699258X09001247/v1_201305061824/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S1699258X0900031X"
    "issn" => "1699258X"
    "doi" => "10.1016/j.reuma.2009.01.002"
    "estado" => "S300"
    "fechaPublicacion" => "2010-01-01"
    "aid" => "30"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L"
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "sco"
    "cita" => "Reumatol Clin. 2010;6:1-2"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 15587
      "formatos" => array:3 [
        "EPUB" => 141
        "HTML" => 14131
        "PDF" => 1315
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
      "titulo" => "Gen&#233;tica del lupus eritematoso generalizado&#46; &#191;Qu&#233; se sabe y a d&#243;nde se va&#63;"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "1"
          "paginaFinal" => "2"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Systemic lupus erythematosus&#46; &#171;What do we know and where are we heading&#63;&#187;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Marta Eugenia Alarc&#243;n Riquelme"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Marta Eugenia"
              "apellidos" => "Alarc&#243;n Riquelme"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X0900031X?idApp=UINPBA00004M"
    "url" => "/1699258X/0000000600000001/v1_201305061824/S1699258X0900031X/v1_201305061824/es/main.assets"
  ]
  "en" => array:11 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>"
    "titulo" => "New drugs for rheumatoid arthritis&#58; The industry point of view"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "3"
        "paginaFinal" => "4"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Stephen H&#46; Polmar"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Stephen H&#46;"
            "apellidos" => "Polmar"
            "email" => array:1 [
              0 => "stephen&#64;polmarconsulting&#46;com"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:1 [
            "entidad" => "Polmar Pharma Consulting&#44; Woodbridge&#44; Connecticut&#44; USA"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Nuevos medicamentos contra la artritis reumatoide&#46; El punto de vista de la industria"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p class="elsevierStylePara elsevierViewall">During the past decade there has been impressive progress in the treatment of rheumatoid arthritis &#40;RA&#41;&#46; Beginning with the regulatory approvals of etanercept and leflunomide in 1998&#44; a total of 10 new disease-modifying anti-rheumatic drugs &#40;DMARDs&#41; have been approved for the treatment of RA&#46; Of these 10 drugs&#44; 9 are biologicals &#40;i&#46;e&#46; monoclonal antibodies&#44; soluble receptors or fusion proteins&#41; and only one&#44; leflunomide&#44; is a small molecule&#44; non-biological DMARD&#46; The biologicals include 5 TNF-blocking agents &#40;etanercept&#44; infliximab&#44; adalimumab&#44; golimumab and certolizumab pegol&#41;&#44; an IL-1 beta blocking recombinant soluble receptor &#40;anakinra&#41;&#44; a T-cell co-stimulatory receptor blocking fusion protein &#40;CTLA4-Ig&#44; abatacept&#41;&#44; a B-cell depleting monoclonal antibody &#40; anti-CD20&#44; rituximab&#41; and most recently&#44; a monoclonal antibody directed against the IL-6 receptor &#40;tocilizumab&#41;&#46; This is an impressive record for this sector of the pharmaceutical industry during a period when the overall productivity of the industry&#44;as measured by the introduction of new drugs to the market&#44; declined&#46;</p><p class="elsevierStylePara elsevierViewall">While currently therapy for new patients with RA is initiated with one or more non-biological DMARDs &#40;most frequently methotrexate&#41;&#44; supplemented with non-steroidal anti-inflammatory drugs &#40;NSAIDS&#41; and corticosteroids&#44; the advent of the biological agents has fostered earlier and more aggressive therapy<a class="elsevierStyleCrossRef" href="#bib1"><span class="elsevierStyleSup">1</span></a>&#46; For many patients with an inadequate response to non-biological DMARDs&#44; addition of a TNF blocking agent results in a significant improvement in signs and symptoms of disease as measured by American College of Rheumatology &#40;ACR&#41; scores&#46; Furthermore&#44; as demonstrated in the Premier study&#44; the combination of methotrexate with an anti-TNF alpha monoclonal antibody showed superior efficacy compared to either drug used as monotherapy for patients with early aggressive disease who are na&#239;ve to methotrexate<a class="elsevierStyleCrossRef" href="#bib2"><span class="elsevierStyleSup">2</span></a>&#46; The most stringent regulatory criterion of efficacy in clinical development is &#8220;Major Clinical Response&#8221;&#44; defined as the patient achieving an ACR 70 response for a continuous period of six months&#46; In the Premier study after 2 years&#44; 49&#37; of patients in the combination therapy group achieved a Major Clinical Response compared to 28&#37; and 25&#37; for methotrexate alone and adalimumab alone&#44; respectively&#46; In the development of new drugs for RA&#44; pharmaceutical companies chose a so-called &#8220;Gold Standard&#8221; therapy to which all new therapeutic agents will be compared with respect to efficacy and safety&#46; For this purpose&#44; most pharmaceutical companies now consider the combination of methotrexate with a TNF-blocking agent as the Gold Standard for RA treatment&#46;</p><p class="elsevierStylePara elsevierViewall">When considering investment in a drug discovery and drug development program&#44; a pharmaceutical company must consider the unmet medical need in a particular disease&#44; the size of the patient population anticipated at the time the new drug will enter the market and the competition from other companies&#46; Most importantly the pharmaceutical company must attempt to determine if the mechanism of action of the new drug will translate into increased efficacy and an acceptable safety profile to permit both the approval of the drug by regulatory authorities and allow it to compete successfully against drugs that will be on the market&#46; Ultimately&#44; the success or failure of a new drug depends upon its ability achieve &#8220;market penetration&#8221;&#44; that is to gain a larger share of the market than its competitors&#46;</p><p class="elsevierStylePara elsevierViewall">At the present time rheumatologists and their patients are reasonably satisfied with the Gold Standard therapy with respect to both its degree of efficacy and safety&#44; but clearly there is room for improvement&#46; Gold Standard therapy achieves a Major Clinical Response in only half of the patients and approximately 30&#37; do not even achieve an ACR 20 response&#46; However&#44; the consensus among pharmaceutical companies is that the new biologicals currently in clinical development are unlikely to displace the TNF blocking agents which they consider &#8220;first-line biological therapy&#8221;&#46; This is due both to their efficacy and the generally favorable 15-year safety record of these agents&#46; In contrast&#44; the biologicals currently used in &#8220;second-line biological therapy&#8221; such as anakinra&#44; abatacept&#44; rituximab and tocilizumab may be vulnerable to replacement due either to sub-optimal efficacy or unanswered questions about their long-term safety&#46; Two anti-CD20 B-cell depleting antibodies&#44; ocrelizumab and ofatumumab&#44; are being positioned as replacements for rituximab&#46; However&#44; a potential complicating factor&#44; not only for the companies developing anti-CD 20 monoclonal antibodies&#44; but also for those companies currently marketing and developing other biologicals&#44; is the possible entry of generic biologicals into the market place in near future&#46; Starting with the expiry of the etanercept patent in 2012 in the US&#44; the patents for all current first and second line biologicals will expired by 2018&#46; The potential impact of generic biologicals on the market is unknown at this time and will depend to a great extent upon the regulatory requirements for generic biologicals and the ability of pharmaceutical companies to delay their entry into the market by legal action&#46; Nonetheless&#44; there should still be opportunities for new biologicals which act on new targets or by novel mechanisms to penetrate the RA market provided that they can demonstrate superior efficacy to currently available biologicals and acceptable safety profiles&#46; For example&#44; anti-IL-17 monoclonal antibodies&#44; which has shown remarkable efficacy in psoriasis&#44; are now in clinical trials in RA&#46; Other biologicals in early clinical development include anti-IL-18&#44; anti-IL-18 receptor&#44; anti-CD 16&#44; anti-GMCSF and anti-IP-10&#46;</p><p class="elsevierStylePara elsevierViewall">Many in the pharmaceutical industry believed that the era of biological DMARD therapy for RA would be relatively short and would be a transitional period after which the biologicals would be largely replaced by oral small molecule therapies&#46; This has been shown to be incorrect&#46; The development of new oral therapies has proven to be extremely challenging both with respect to achieving adequate efficacy and acceptable safety&#46; The attrition of new small molecule drugs in RA clinical development has been extremely high&#46; For example&#44; in 2007 seven pharmaceutical companies had p38 MAP kinase inhibitors in phase II and now only one remains&#46; There is a long list of compounds whose development has been recently discontinued including chemokine inhibitors &#40;CCR1 and CCR2&#41;&#44; an iNOS inhibitor&#44; IKK-2 inhibitor and P2X7 receptor antagonists&#46; There are&#44; however&#44; two small molecule drug classes that are currently in late stage clinical development&#44; janus-associated kinase &#40;JAK&#41; inhibitors and spleen tyrosine kinase &#40;SYK&#41; inhibitors&#46; These drugs have shown efficacy similar to TNF-blocking agents in phase II clinical trials&#44; but safety concerns exist such as elevation of liver enzymes and LDL cholesterol&#44; the clinical significance of which remain to be determined&#46; The goal of pharmaceutical companies developing oral small molecule therapeutic agents is to attempt to replace the first-line biologicals in patients who have had an inadequate response to methotrexate&#46; To achieve this goal&#44; these new drugs will have to be at least as efficacious as the TNF-blockers and also have an acceptable safety profile that permits co-administration with methotrexate without an additional risk of hepatotoxicity&#46; Alternatively&#44; such compounds would have to show efficacy as monotherapy comparable to a TNF-blocking agent &#43; methotrexate&#46; These new oral DMARDS would have a potential competitive advantage of convenience for patients and would be expected to cost less than the biologicals&#44; therefore being favored by health authorities and insurance companies&#46; However&#44; the extent to which some of the new oral agents will ultimately penetrate the market will depend on their efficacy in phase III trials and safety profiles&#44; the degree to which patients will favor daily oral therapy versus every other week or monthly injections and also the possible entry of generic biologicals into the market at a substantially lower cost than current brand-name biologicals&#46;</p><p class="elsevierStylePara elsevierViewall">The pharmaceutical industry&#44; together with academic researchers&#44; has explored many potential drug targets for RA therapy&#46; While there have been some successes there have been many more failures&#44; nonetheless&#44; pharmaceutical companies continue to invest in research and development of new drugs for RA&#46; At the present time&#44; approximately 65 drugs are in phase I or phase II&#44; 63&#37; of these are biologicals and 37&#37; are small molecules&#46; The overwhelming majority of these drugs target the immune system&#46; In a disease such as RA in which combination therapy is frequently employed&#44; addition of yet another drug that targets the immune system along with the Gold Standard therapy can result in an unacceptably high incidence of severe infections&#46; In recognition of the limit to which the immune system can be safely manipulated&#44; academic researchers&#44; biotech companies and some pharmaceutical companies are starting to focus on other tissues &#40;e&#46;g&#46; synovial fibroblasts and osteoclasts&#41; or processes &#40;e&#46;g&#46; angiogenesis&#41; which play an important role in the pathogenesis of RA but which are not critical for host defense against infection or malignancy&#46;</p><p class="elsevierStylePara elsevierViewall">In the next 5&#8211;10 years&#44; rheumatologists and their patients should not expect a rate of introduction of new drugs for RA as high as that which occurred during the last decade&#46; However&#44; since a substantial number of patients still do not have their disease fully controlled by current therapy&#44; one can anticipate that the pharmaceutical industry will continue to invest in research and development of both biological- and non-biological drugs to meet the needs of these patients&#46;</p></span>"
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:2 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46;G&#46; Saag"
                            1 => "G&#46;G&#46; Teng"
                            2 => "N&#46;M&#46; Patkar"
                            3 => "J&#46; Anuntiyo"
                            4 => "C&#46; Finney"
                            5 => "J&#46;R&#46; Curtis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.23721"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2008"
                        "volumen" => "59"
                        "paginaInicial" => "762"
                        "paginaFinal" => "784"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18512708"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The PREMIER study&#58; A multicenter&#44; randomized&#44; double-blind&#44; clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early&#44; aggressive rheumatoid arthritis who had not had previous methotrexate treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "F&#46;C&#46; Breedveld"
                            1 => "M&#46;H&#46; Weisman"
                            2 => "A&#46;F&#46; Kavanaugh"
                            3 => "S&#46;B&#46; Cohen"
                            4 => "K&#46; Pavelka"
                            5 => "R&#46; van Vollenhoven"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.21519"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum"
                        "fecha" => "2006"
                        "volumen" => "54"
                        "paginaInicial" => "26"
                        "paginaFinal" => "37"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16385520"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/1699258X/0000000600000001/v1_201305061824/S1699258X0900240X/v1_201305061824/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "17498"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Editorial"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/1699258X/0000000600000001/v1_201305061824/S1699258X0900240X/v1_201305061824/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X0900240X?idApp=UINPBA00004M"
]
Información del artículo
ISSN: 1699258X
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 8 6 14
2024 Octubre 136 50 186
2024 Septiembre 145 19 164
2024 Agosto 141 53 194
2024 Julio 116 31 147
2024 Junio 135 34 169
2024 Mayo 129 56 185
2024 Abril 136 29 165
2024 Marzo 109 34 143
2024 Febrero 97 26 123
2024 Enero 99 31 130
2023 Diciembre 79 31 110
2023 Noviembre 98 23 121
2023 Octubre 101 27 128
2023 Septiembre 116 44 160
2023 Agosto 57 20 77
2023 Julio 74 26 100
2023 Junio 91 29 120
2023 Mayo 95 36 131
2023 Abril 81 24 105
2023 Marzo 118 43 161
2023 Febrero 94 36 130
2023 Enero 97 32 129
2022 Diciembre 85 33 118
2022 Noviembre 113 46 159
2022 Octubre 133 51 184
2022 Septiembre 136 44 180
2022 Agosto 144 45 189
2022 Julio 125 58 183
2022 Junio 115 63 178
2022 Mayo 126 85 211
2022 Abril 139 62 201
2022 Marzo 157 70 227
2022 Febrero 202 38 240
2022 Enero 212 55 267
2021 Diciembre 188 53 241
2021 Noviembre 145 50 195
2021 Octubre 174 69 243
2021 Septiembre 217 50 267
2021 Agosto 234 57 291
2021 Julio 179 40 219
2021 Junio 224 52 276
2021 Mayo 211 56 267
2021 Abril 370 165 535
2021 Marzo 289 33 322
2021 Febrero 155 42 197
2021 Enero 197 49 246
2020 Diciembre 166 15 181
2020 Noviembre 149 37 186
2020 Octubre 140 33 173
2020 Septiembre 197 51 248
2020 Agosto 149 22 171
2020 Julio 109 27 136
2020 Junio 138 38 176
2020 Mayo 201 30 231
2020 Abril 150 34 184
2020 Marzo 171 25 196
2020 Febrero 139 26 165
2020 Enero 113 27 140
2019 Diciembre 117 42 159
2019 Noviembre 98 22 120
2019 Octubre 134 43 177
2019 Septiembre 130 34 164
2019 Agosto 90 33 123
2019 Julio 78 22 100
2019 Junio 73 39 112
2019 Mayo 112 75 187
2019 Abril 84 34 118
2019 Marzo 89 26 115
2019 Febrero 52 30 82
2019 Enero 60 41 101
2018 Diciembre 75 54 129
2018 Noviembre 92 13 105
2018 Octubre 60 9 69
2018 Septiembre 51 10 61
2018 Agosto 55 7 62
2018 Julio 27 5 32
2018 Mayo 3 0 3
2018 Abril 63 7 70
2018 Marzo 77 3 80
2018 Febrero 40 4 44
2018 Enero 45 5 50
2017 Diciembre 35 5 40
2017 Noviembre 38 5 43
2017 Octubre 61 11 72
2017 Septiembre 39 9 48
2017 Agosto 26 8 34
2017 Julio 37 11 48
2017 Junio 54 12 66
2017 Mayo 70 9 79
2017 Abril 50 9 59
2017 Marzo 61 8 69
2017 Febrero 65 7 72
2017 Enero 68 9 77
2016 Diciembre 72 22 94
2016 Noviembre 87 12 99
2016 Octubre 101 7 108
2016 Septiembre 86 3 89
2016 Agosto 32 3 35
2016 Julio 21 7 28
2016 Junio 2 0 2
2016 Mayo 1 0 1
2016 Marzo 1 0 1
2016 Febrero 3 0 3
2015 Diciembre 2 0 2
2015 Noviembre 1 0 1
2015 Octubre 1 0 1
2015 Septiembre 5 0 5
2015 Agosto 2 0 2
2015 Julio 15 6 21
2015 Junio 27 6 33
2015 Mayo 65 16 81
2015 Abril 65 15 80
2015 Marzo 55 6 61
2015 Febrero 63 0 63
2015 Enero 71 0 71
2014 Diciembre 65 0 65
2014 Noviembre 46 0 46
2014 Octubre 60 0 60
2014 Septiembre 52 0 52
2014 Agosto 55 0 55
2014 Julio 70 0 70
2014 Junio 84 0 84
2014 Mayo 56 0 56
2014 Abril 46 0 46
2014 Marzo 63 14 77
2014 Febrero 47 13 60
2014 Enero 44 10 54
2013 Diciembre 39 11 50
2013 Noviembre 48 5 53
2013 Octubre 44 10 54
2013 Septiembre 39 8 47
2013 Agosto 26 13 39
2013 Julio 33 4 37
2013 Junio 25 7 32
2013 Mayo 21 5 26
2013 Abril 23 9 32
2013 Marzo 32 10 42
2013 Febrero 32 7 39
2013 Enero 14 2 16
2012 Diciembre 15 2 17
2012 Noviembre 15 12 27
2012 Octubre 15 9 24
2012 Septiembre 16 4 20
2011 Mayo 2 0 2
2011 Abril 4 0 4
2011 Marzo 13 0 13
2011 Febrero 6 0 6
2011 Enero 5 0 5
2010 Diciembre 1 0 1
2010 Octubre 2 0 2
2010 Julio 1 0 1
2010 Junio 4 0 4
2010 Mayo 15 0 15
2010 Abril 4 0 4
2010 Febrero 9 0 9
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Reumatología Clínica
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?